Expresión de la enzima Iduronato Sulfatasa en pichia pastoris :estudios de su modelo de glicosilación. Posible uso de la enzima en terapia de reemplazo enzimático

IP 1203-12-10410Incluye anexos.Colombia / P. Sarmiento ... [et al.] -- p. 38 -- En: International Symposium on Novel Therapies for Lysosomal;Storage Disroders. (2001 Nov. 29-Dec. 1 : Canela, Brazil)-- [s.l : s.n],2001 -- p. ; 28 cm. -- Prediccion;computacional de las estructuras secundaria y terciaria delaiduronato 2-sulfato sulfatasa (ids) y modelos de;PONENCIA(S) EN CONGRESO: Expression of the human recombinant iduronate 2-sulfate sulfatase (hrids) in Pichia;Pastoris / Patricia Landazuri ... [et al.] -- En: Annual WorldSymposium on Lysosomal Storage Disorders (2002;: Baltimore) -- [s.l : s.n], 2002 -- p. ; 28 cm. -- Preliminarymolecularstudy of morquio syndrome in;de la iduronato-2 sulfato sulfatasa humana recombinante funcionalmente activa en Escherichia coli / Patricia;Landazuri. [et al.] -- p. 115 -- En: Congreso Nacional deCiencias Biologicas. (37 : 2002 oct. 1-4 : San Juan;de Pasto, Colombia). -- [s.l : s.n], 2002 -- p. ; 22 cm. -'- Estudios computacionales sobre las glicosilaciones;de la iduronato-2 sulfatasa / L. Lareo, M.A. Gutierrez, L.A. Barrera. -- p. 41 -- En: Congreso Latinoamericano;de Errores Innatos del Metabolismo y Pesquisa Neonatal, Encuentro Internacional en Screening Neonatal (3, 3 :;2001 oct. 21-24 : Cartagena, Colombia) -- [s-l : s.n], 2001 --p. ; 28 cm.;su sitio activo / Edgar Reyes, Leonardo Lareo, Luis AlejandroBarrera. --En: Congreso Nacional de Genetica;Humana. (27 : 2002 nov. 20-23 : Veracruz, Mexico). -- [s.l:s.n], 2002 --p. ; 28 cm. -- Expresion trasient

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

International audienceSignificance There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important to estimate their quantitative impact on COVID-19 mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence of these autoantibodies and the risk of COVID-19 death increase with age and are higher in men. Using an unvaccinated sample of 1,261 deceased patients and 34,159 individuals from the general population, we found that autoantibodies against type I IFNs strongly increased the SARS-CoV-2 infection fatality rate at all ages, in both men and women. Autoantibodies against type I IFNs are strong and common predictors of life-threatening COVID-19. Testing for these autoantibodies should be considered in the general population

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

International audienceSignificance There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important to estimate their quantitative impact on COVID-19 mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence of these autoantibodies and the risk of COVID-19 death increase with age and are higher in men. Using an unvaccinated sample of 1,261 deceased patients and 34,159 individuals from the general population, we found that autoantibodies against type I IFNs strongly increased the SARS-CoV-2 infection fatality rate at all ages, in both men and women. Autoantibodies against type I IFNs are strong and common predictors of life-threatening COVID-19. Testing for these autoantibodies should be considered in the general population